ISBN : 978-93-85073-24-3 Title: Polymeric Nanocarriers for the Dissolution of Anti-Depressants Drugs by using Kinetic Model Ram Prakash Aharwal*, Sandeep Kumar Shukla*, Archna Pandey* Department of Chemistry Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar (M.P) 470003 E-mail Id: rpaharwal9@gmail.com, prof.archnapandey@gmail.com In general, the development of drug nanocarriers for poorly soluble pharmaceuticals represents a special task and still faces some unresolved issues. The therapeutic application of hydrophobic, poorly water-soluble agents is associated with some serious problems, since low water-solubility results in poor absorption and low bioavailability [1]. In addition, drug aggregation upon intravenous administration of poorly soluble drugs might lead to such complications as embolism [2] and local toxicity [3]. On the other hand, the hydrophobicity and low solubility in water appear to be intrinsic properties of many drugs [4], since it helps a drug molecule to penetrate a cell membrane and reach important intracellular targets [5-6]. To overcome the poor solubility of certain drugs, clinically acceptable organic solvents are used in their formulations, as well as liposomes [7]. Another alternative is associated with the use of various micelle-forming surfactants in formulations of insoluble drugs. Delivering water-insoluble drugs, reducing severe systemic toxicities and increasing the utilization of drugs by improving their pharmacokinetics posed many challenges for drug delivery system (DDS) and drug development [8]. Recently, several type of drug carrier, such as microspheres, liposomes, nanoparticles [9] and polymeric carriers have been investigated as DDS, but non-selective scavenging of these carriers by the reticuloendothelial system (RES) is a serious problem. The structure of nanocarriers first developed in 1970 has since been optimized in order to improve their biodistribution. Polyethylene glycol (PEG) is grafted to nanoparticles and liposomes, increasing their stealth capacity and consequently, their systemic residence time in the blood-stream [10]. Nanocarriers injected by the systemic route and used for drug delivery have to respect some essential conditions [11]. 1
7 Publizr Home